Innovotech Inc. Announces Intent to Pursue OTCQB Venture Market Listing

Innovotech Inc. has announced its intention to obtain a stock quotation in the United States and a trading symbol on the OTC Markets OTCQB venture market. This strategic move aims to enhance the company's visibility to the investment community with the goal of making it more accessible to retail and institutional investors in the United States and increasing the liquidity of the company. The OTCQB quotation will operate in parallel with the company's primary Canadian listing on the TSX Venture Exchange under the symbol IOT.

The importance of this announcement lies in its potential to broaden Innovotech's investor base significantly. By gaining access to U.S. markets through the OTCQB, the company positions itself to attract capital from one of the world's largest investment markets. This expansion comes with minimal additional compliance burdens, as the OTCQB quotation is expected to impose no additional material compliance or reporting requirements. As a foreign private issuer, Innovotech will continue to meet its existing primary market disclosure obligations on SEDAR+, which satisfy OTC market requirements under established foreign issuer exemptions.

To be considered for admission to the OTCQB, companies must meet certain financial standards, be current in their reporting obligations, and undergo an annual verification and management certification process. In conjunction with the listing, the company will also apply for eligibility with the Depository Trust Company, enabling simplified electronic clearing and settlement of its common shares for U.S. investors. This dual approach of pursuing both OTCQB listing and DTC eligibility demonstrates a comprehensive strategy to facilitate U.S. market participation.

The implications of this move extend beyond mere market access. For a specialized contract research organization like Innovotech, increased visibility in U.S. markets could lead to enhanced recognition among potential clients and partners in sectors where the company operates, including pharmaceutical analysis and industrial laboratory solutions. The company's proprietary technologies, such as its widely-used MBEC Assay® kit for high-throughput antimicrobial and antibiotic testing, may gain broader exposure through this expanded market presence. The announcement represents a calculated step toward growth without substantially increasing regulatory burdens, leveraging existing reporting frameworks while tapping into new capital markets. Additional information about the company is available at https://www.innovotech.ca.